ECE1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human A-549 lung adenocarcinoma cell line, in which the ECE1 gene has been disrupted to create a loss-of-function model for endothelin-converting enzyme-1 (ECE-1). This polyclonal population, derived through CRISPR/Cas9-mediated gene disruption, provides a heterogeneous knockout model that reflects the genetic complexity of tumor cell populations. It is designed for researchers investigating ECE1-dependent signaling, tumorigenesis, and pharmacological modulation in a physiologically relevant epithelial background.
The host A-549 cell line is a well-established human lung adenocarcinoma model originally isolated from a 58-year-old male. These cells display an epithelial morphology and are widely used to study alveolar type II pneumocyte biology, non-small-cell lung cancer pathology, and respiratory disease mechanisms. A-549 cells retain key signaling pathways characteristic of lung adenocarcinoma, making them a robust platform for dissecting oncogenic processes and evaluating targeted therapies.
ECE1 encodes a type II integral membrane zinc metalloprotease that primarily converts big endothelin-1 to the active vasoconstrictor and mitogen endothelin-1 (EDN1). Additionally, ECE-1 degrades other vasoactive peptides, including bradykinin and substance P, through interactions with substrates such as BDKRB2. The transcription of ECE1 is regulated by HIF1A, AP-1, NF-??B, TGF-??, and TNF-??, and is responsive to hypoxia and shear stress. Once processed, EDN1 binds to its cognate receptors EDNRA and EDNRB, activating GNAQ?mediated PLCB signaling and downstream kinases MAPK1 and AKT1, which in turn phosphorylate effectors like PTGS2, VEGFA, and RHOA. This cascade culminates in the transcriptional activity of NFAT and CREB, driving proliferation, migration, and survival programs. ECE-1 also physically interacts with KEL and PI4K2A, further integrating its function into broader proteolytic networks.
In the context of A-549 lung adenocarcinoma cells, disruption of ECE1 abrogates endothelin-1 production, thereby attenuating EDNRA/EDNRB-mediated activation of the MAPK/ERK and PI3K/AKT axes. This knockout model impairs key tumorigenic properties??including cell proliferation, migration, invasion, and survival??allowing researchers to dissect the contribution of ECE1 to lung adenocarcinoma progression. The polyclonal nature of the knockout population ensures that the model recapitulates the heterogeneity observed in clinical tumors, making it especially suitable for studying tumor microenvironment interactions and adaptive signaling rewiring upon loss of ECE1 function.
Typical applications of ECE1 Knockout A-549 Polyclonal Cells include mechanistic studies of endothelin signaling in lung cancer, screening of ECE1 inhibitors or endothelin receptor antagonists, and investigation of metastasis and invasion pathways. These cells are compatible with a range of molecular and functional assays, such as western blotting for phospho-ERK/AKT analysis, RT-qPCR and RNA-seq for transcriptomic profiling, ELISA for endothelin-1 quantification, proliferation assays (MTT/CCK-8), transwell migration/invasion assays, and apoptosis assessment. By providing a clean loss-of-function background, this knockout model enables precise dissection of ECE1-dependent phenotypes and facilitates the identification of novel therapeutic targets. For additional details or to inquire about custom gene-editing services, please contact Ascent Research.
